MET Targeted Therapy for NSCLC

EP. 1: Impact of Driver Mutations in NSCLC

March 23rd 2020

EP. 2: Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC

March 23rd 2020

EP. 3: FDA Priority Review of Capmatinib for METex14-Mutated NSCLC

March 23rd 2020

EP. 4: The Availability of MET Inhibitors for NSCLC

March 23rd 2020

EP. 5: Benefit of Alpelisib/Fulvestrant Combo in HR+/HER- Breast Cancer Confirmed With Biomarker Analysis

ByBrittany Lovely

June 5th 2022

Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.

MET Targeted Therapy for NSCLC

EP. 1: Impact of Driver Mutations in NSCLC

EP. 2: Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC

EP. 3: FDA Priority Review of Capmatinib for METex14-Mutated NSCLC

EP. 4: The Availability of MET Inhibitors for NSCLC

EP. 5: Benefit of Alpelisib/Fulvestrant Combo in HR+/HER- Breast Cancer Confirmed With Biomarker Analysis

Trending on Targeted Onc

ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care

Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026

ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care

340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent

Lenvatinib Plus Pembro Remains Frontline Standard in RCC